Ono Pharmaceuticals announced that nivolumab has been approved in Asia. It obtained the rights to nivolumab from Medarex in 2005. It is approved for use in patients with unresectable melanoma.
Immune checkpoint control is the hottest area in cancer immunology. Indeed, the checkpoint inhibitors have shown great activity in a variety of cancers. This article http://online.wsj.com/article/PR-CO-20140506-908279.html) summarizes 2 approaches that Merck is taking… Continue reading